Accredo helps patients manage the unique complexities of a rare disease with best-in-class clinical care while supporting payers with appropriate management strategies.
Indication-specific pricing makes therapy more affordable and accessible for all patients by aligning payment for a drug with the value it delivers to a particular patient population.
Getting to the Rare Diagnosis: 7.6 Years and 7 Different Doctors
For patients with rare disease, getting to the right diagnosis is just the beginning of their journey. Our Rare Conditions Care Value Program® offers personalized support to help patients manage their...
SafeGuardRx: Delivering Better Health and Affordability
This first-to-market value-based program improves patient engagement and increases medication adherence while reducing costs for some of the costliest therapies.
Nonadherence Puts Patients With Multiple Sclerosis on a Dangerous Path
Patients diagnosed with multiple sclerosis (MS) face unpredictable and increasingly debilitating symptoms. Nonadherence can make these adverse events more costly and dangerous.
SafeGuardRx: Better Care at a Lower Cost for Patients and Payers
New data shows significantly improved clinical outcomes and lower drug spending for patients with complex, high-cost conditions enrolled in our SafeGuardRxSM programs.
Working with Regeneron and Sanofi, Express Scripts directly delivers drug-specific savings to patients, making PCSK9 therapy more affordable and more accessible.
Patients with inflammatory conditions and multiple sclerosis can overcome barriers to taking their medications with the help of financial assistance programs.
Express Scripts Flattens the Trajectory of the Diabetes Epidemic with SafeGuardRx Diabetes Care Value® Program
In its first year, the Express Scripts Diabetes Care Value program delivered nearly $43 million savings for plans; reduced heart attack risk in 15 percent of patients
